DM increases the risk of various cardiovascular events (e.g., HF, coronary artery disease, AF) and cardiovascular deaths [17–19], and therefore, clinical trials demonstrating the robust cardiovascular benefits of SGLT2 inhibitors for patients with DM, revolutionized clinical practice [1–3]. The gene discussed is SLC5A2; the disease is atrial fibrillation.